PDF(Pubmed)
Abstract：
BACKGROUND: Cases of autoimmune bullous dermatosis (AIBD) have been reported following COVID-19 vaccination.
OBJECTIVE: We aimed to provide an overview of clinical characteristics, treatments, and outcomes of AIBDs following COVID-19 vaccination.
METHODS: We conducted a systematic review and searched the Embase, Cochrane Library, and Medline databases from their inception to 27 March 2024. We included all studies reporting ≥ 1 patient who developed new-onset AIBD or experienced flare of AIBD following at least one dose of any COVID-19 vaccine.
RESULTS: We included 98 studies with 229 patients in the new-onset group and 216 in the flare group. Among the new-onset cases, bullous pemphigoid (BP) was the most frequently reported subtype. Notably, mRNA vaccines were commonly associated with the development of AIBD. Regarding the flare group, pemphigus was the most frequently reported subtype, with the mRNA vaccines being the predominant vaccine type. The onset of AIBD ranged from 1 to 123 days post-vaccination, with most patients displaying favorable outcomes and showing improvement or resolution from 1 week to 8 months after treatment initiation.
CONCLUSIONS: Both new-onset AIBD and exacerbation of pre-existing AIBD may occur following COVID-19 vaccination. Healthcare practitioners should be alert, and post-vaccination monitoring may be essential.
OBJECTIVE: We aimed to provide an overview of clinical characteristics, treatments, and outcomes of AIBDs following COVID-19 vaccination.
METHODS: We conducted a systematic review and searched the Embase, Cochrane Library, and Medline databases from their inception to 27 March 2024. We included all studies reporting ≥ 1 patient who developed new-onset AIBD or experienced flare of AIBD following at least one dose of any COVID-19 vaccine.
RESULTS: We included 98 studies with 229 patients in the new-onset group and 216 in the flare group. Among the new-onset cases, bullous pemphigoid (BP) was the most frequently reported subtype. Notably, mRNA vaccines were commonly associated with the development of AIBD. Regarding the flare group, pemphigus was the most frequently reported subtype, with the mRNA vaccines being the predominant vaccine type. The onset of AIBD ranged from 1 to 123 days post-vaccination, with most patients displaying favorable outcomes and showing improvement or resolution from 1 week to 8 months after treatment initiation.
CONCLUSIONS: Both new-onset AIBD and exacerbation of pre-existing AIBD may occur following COVID-19 vaccination. Healthcare practitioners should be alert, and post-vaccination monitoring may be essential.
摘要：
背景：在COVID-19疫苗接种后，已经报道了自身免疫性大疱性皮肤病（AIBD）的病例。
目的：我们旨在概述临床特征，治疗,和COVID-19疫苗接种后AIBDs的结果。
方法：我们进行了系统回顾并搜索了Embase，科克伦图书馆,和Medline数据库从成立到2024年3月27日。我们纳入了所有报告≥1名患者的研究，这些患者在至少一剂任何COVID-19疫苗后出现新发AIBD或AIBD发作。
结果：我们纳入了98项研究，其中新发病例组229名患者，耀斑组216名患者。在新发病例中,大疱性类天疱疮（BP）是最常见的亚型。值得注意的是,mRNA疫苗通常与AIBD的发展有关。关于耀斑组，天疱疮是最常见的亚型，mRNA疫苗是主要的疫苗类型。AIBD的发病范围为接种疫苗后1至123天，大多数患者在治疗开始后1周至8个月表现出良好的结局，并表现出改善或消退。
结论：新发AIBD和先前存在的AIBD的恶化都可能在接种COVID-19疫苗后发生。医疗保健从业者应该保持警惕，疫苗接种后的监测可能是必不可少的。
目的：我们旨在概述临床特征，治疗,和COVID-19疫苗接种后AIBDs的结果。
方法：我们进行了系统回顾并搜索了Embase，科克伦图书馆,和Medline数据库从成立到2024年3月27日。我们纳入了所有报告≥1名患者的研究，这些患者在至少一剂任何COVID-19疫苗后出现新发AIBD或AIBD发作。
结果：我们纳入了98项研究，其中新发病例组229名患者，耀斑组216名患者。在新发病例中,大疱性类天疱疮（BP）是最常见的亚型。值得注意的是,mRNA疫苗通常与AIBD的发展有关。关于耀斑组，天疱疮是最常见的亚型，mRNA疫苗是主要的疫苗类型。AIBD的发病范围为接种疫苗后1至123天，大多数患者在治疗开始后1周至8个月表现出良好的结局，并表现出改善或消退。
结论：新发AIBD和先前存在的AIBD的恶化都可能在接种COVID-19疫苗后发生。医疗保健从业者应该保持警惕，疫苗接种后的监测可能是必不可少的。
